Loading
companiesCompany
Dren Bio
Dren Bio is a Californian biotech whose bispecific antibodies recruit macrophages to engulf diseased cells; DR-01 directs this against CD94 to clear the cancerous cells of T-cell and natural killer cell lymphomas.
Also called: Dren Bio, Inc.
Overview
Dren Bio develops targeted myeloid engagers, bispecific antibodies that bind a disease antigen on one arm and a phagocytic receptor on macrophages with the other, so the target cell is engulfed. DR-01, its first clinical programme, depletes CD94-expressing cytotoxic lymphocytes and is in a phase 1/2 study in large granular lymphocytic leukaemia and cytotoxic lymphomas. Its CD20-directed engager DR-0201 for autoimmune disease was licensed to Sanofi in 2025.
Headquarters
Foster City, California, US
Scorecard
All companies#460of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Monoclonal antibody
DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas.
drugs
Phase 2Monoclonal antibody